CNE100004ZK3
CNE100004ZK3
NANJING VAZYME BIOTECH CO LTD
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 13.75B EUR | 8.97B EUR | 7.78B EUR | 7.96B EUR |
Enterprise Value | 11.9B EUR | 9.22B EUR | 7.88B EUR | 8B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 72.04x | -- | -- | -- |
Price to Sales | 9.34x | 7.97x | 7.28x | 7.72x |
Price to Book | 3.81x | 2.48x | 2.05x | 2.1x |
EV/Revenue | 8.09x | 8.18x | 7.38x | 7.75x |
EV/EBITDA | -2,187.89x | 662.97x | 1,245.18x | -- |
Price to FCF (P/FCF) | 61.85x | 52.9x | 64.13x | 57.22x |
EV/FCF | 53.54x | 54.35x | 64.97x | 57.49x |
FCF Yield | 1.62% | 1.89% | 1.56% | 1.75% |